Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

被引：0

作者：

Rathkopf, Dana E.

Roubaud, Guilhem

Chi, Kim N.

Efstathiou, Eleni

Attard, Gerhardt

Olmos, David

Small, Eric J.

Saad, Marniza

Castro, Elena

Kim, Won

Wu, Daphne

Bertzos, Kristi

Dibaj, Shiva

Zhang, Jenny

Francis, Peter St. John

Smith, Matthew Raymond

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Inst Bergonie, Dept Med Oncol, Bordeaux, France

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Houston Methodist Hosp, Dept Med Oncol, Houston, TX USA

[5] UCL, London, England

[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre, Madrid, Spain

[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[8] Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia

[9] Univ Hosp Virgen de la Victoria HUVV, Malaga, Spain

[10] Janssen R&D US, Los Angeles, CA USA

[11] Janssen Res & Dev LLC, Los Angeles, CA USA

[12] Janssen Global Commercial Strategy Org, Horsham, PA USA

[13] Janssen Res & Dev LLC, San Diego, CA USA

[14] Johnson&Johnson, Spring House, PA USA

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[17] Harvard Med Sch, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.4_suppl.105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：105 / 105

页数：1

共 50 条

[21] Abiraterone acetate plus prednisone (AAP) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) and prior diethylstilbestrol (DES) therapy: Preliminary results.
Bastos, Diogo Assed
Machado, Marcos Tobias
Panhoca, Renato
Pioner, Giovani Thomaz
Werutsky, Gustavo
Grings, Mariana
Lopes, Lizis
Gonzalez, Francisco
Santos, Telma Murias
Gidekel, Rosemarie
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[22] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Posadas, Edwin M.
Bruce, Justine Yang
Lim, Emerson A.
Petrylak, Daniel Peter
Peng, Weimin
Maul, Raymond Scott
Smit, Hans W.
Tran, Namphuong
Nanus, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[23] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Posadas, Edwin M.
Chit, Kim N.
de Wit, Ronald
de Jonge, Maja J. A.
Attard, Gerhardt
Friedlander, Terence
Yu, Margaret
Hellemans, Peter
Chien, Caly
Abrams, Charlene
Gonzalez, Martha
Trudel, Geralyn C.
Chauhan, Vijay
Saad, Fred
CANCER RESEARCH, 2015, 75
[24] FINAL ANALYSIS OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS RECEIVING FIRST-LINE NIRAPARIB WITH ABIRATERONE ACETATE PLUS PREDNISONE ( MAGNITUDE STUDY)
Olivier, Kara
Smith, Matthew
Rathkopf, Dana E.
Small, Eric
Guckert, Mary
Chi, Kim N.
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[25] Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
Thiery-Vuillemin, Antoine
Poulsen, Mads Hvid
Lagneau, Edouard
Ploussard, Guillaume
Birtle, Alison
Dourthe, Louis-Marie
Beal-Ardisson, Dominique
Pintus, Elias
Trepiakas, Redas
Lefresne, Florence
Lukac, Martin
Van Sanden, Suzy
Pissart, Genevieve
Reid, Alison
EUROPEAN UROLOGY, 2020, 77 (03) : 380 - 387
[26] EXPLORATORY ANALYSIS OF THE SAFETY PROFILE OF ABIRATERONE ACETATE (AA) IN PATIENTS (PTS) RECEIVING CONCOMITANT RADIATION THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Saad, Fred
Molina, Arturo
Li, Justin
Thian Kheoh
Scher, Howard I.
JOURNAL OF UROLOGY, 2012, 187 (04): : E278 - E278
[27] Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Chi, K. N.
Spratlin, J.
Kollmannsberger, C.
North, S.
Pankras, C.
Chien, C.
Gonzalez, M.
Pang, L.
Yu, M. K.
Tran, N. P.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S697
[28] Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.
Hao, Yanni
Cleeland, Charles S.
Gagnon, Dennis
Espindle, Derek
Molina, Arturo
Basch, Ethan M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[29] Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC)
Abida, Wassim
Campbell, David
Patnaik, Akash
Sautois, Brieuc
Shapiro, Jeremy David
Vogelzang, Nicholas J.
Bryce, Alan Haruo
McDermott, Raymond S.
Ricci, Francesco
Rowe, Julie Haewon
Zhang, Jingsong
Loehr, Andrea
Despain, Darrin
Dowson, Melanie
Golsorkhi, Tony
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[30] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Petrylak, Daniel P.
Ratta, Raffaele
Matsubara, Nobuaki
Korbenfeld, Ernesto Pablo
Gafanov, Rustem
Mourey, Loic
Fer, Tilman Todenho Spacing Diaeresis
Gurney, Howard
Kramer, Gero
Bergman, Andre M.
Zalewski, Pawel
De Santis, Maria
Armstrong, Andrew J.
Gerritsen, Winald R.
Pachynski, Russell Kent
Saretsky, Todd L.
Ghate, Sameer R.
Li, Xin Tong
Schloss, Charles
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

← 1 2 3 4 5 →